German pharmaceutical service provider Vetter Pharma is developing a new production facility for the aseptic filling of injectable medicines in the Saarland region of south‑west Germany.
The project forms a key component of the company’s long‑term global expansion strategy and will be developed in multiple stages. The initial phase represents an investment of around €480m ($572.48m).
Recommended White Papers
Recommended Buyers Guides
The company announced the project in June 2024 and formally unveiled its construction plans in January 2026. Groundbreaking is planned for the second quarter of 2026 (Q2 2026), with the start of operations targeted for 2031.
The development is projected to generate at least 1,200 direct jobs, alongside additional indirect employment, and has the potential to support up to 2,000 positions at the location over the longer term.
This initiative is included within Vetter Pharma’s broader €1.5bn investment programme.
Location
The new production facility will be constructed on a 95‑acre (36.4-hectare) industrial site in Saarlouis, Saarland, Germany, formerly occupied by Ford. The location is approximately a five‑hour drive from the company’s headquarters in Ravensburg, which opened in 2020.
Vetter Pharma acquired the Saarlouis property at the end of 2024 for €95m, with support from the gwSaar (Saarland Economic Promotion Corporation), and submitted the building permit application for the German site.
Saarland was chosen following detailed strategic investment assessments, with the region preferred over alternative locations in Baden‑Württemberg, Bavaria, Hesse, Austria and Switzerland.
The plant will be situated in a region eligible for regional aid under Article 107(3)(c) of the Treaty on the Functioning of the EU.
SHS Strukturholding Saar, the investment company of the Saarland region, played a key role in facilitating Vetter Pharma’s acquisition of the industrial site.
Vetter Pharma aseptic fill production facility details
The initial phase of construction for the injectable medicines facility will cover approximately 400,000m² (37,161ft2).
The site will focus on aseptic filling of injectable medicines into vials and syringes, and the assembly and packaging of sterile drug products including prefilled syringes, cartridges and vials. It will be equipped with cGMP‑compliant filling lines and advanced equipment, supported by high‑performance processes designed to maintain stringent sterility standards for injection systems.
The facility is intended to enable the company to serve demand from pharmaceutical and biotechnology customers worldwide.
Financing
In December 2025, the European Commission approved €47m of German state aid for Vetter Pharma to support the establishment of the new plant.
According to the Commission, the measure is intended to support EU objectives related to job creation and regional development, and to contribute to the availability of affordable medicines in line with the Pharmaceutical Strategy for Europe.
Marketing commentary on Vetter Pharma
Vetter Pharma is a contract development and manufacturing organisation (CDMO) headquartered in Ravensburg, Germany. The company employs more than 7,700 people.
The CDMO supports pharmaceutical and biotechnology customers worldwide, providing services spanning drug product development, clinical and commercial aseptic filling, and a broad range of assembly and packaging solutions for vials, syringes and cartridges.
Vetter Pharma offers fill finish manufacturing for substance classes including oligonucleotides, monoclonal antibodies, fusion proteins, peptide hormones, coagulation factors and several complex molecules. The company operates 20 aseptic filling lines across its manufacturing facilities in Europe and the US. It also maintains sales offices in key Asia‑Pacific markets including Japan, China, South Korea and Singapore.
